Trial Profile
A Study to Compare the Clinical Outcomes of Everolimus-Eluting Stent and Resolute-Zotarolimus-Eluting Stent in Acute Myocardial Infarction Patients With and Without Metabolic Syndrome
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Aug 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Zotarolimus (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Acronyms KAMIR
- 30 Jul 2020 Results (n=4377) of retrospective analysis assessing clinical outcomes in patients between DP-based and BP-based newer-generation DESs published in the International Heart Journal
- 05 Jul 2016 New trial record